Insmed (INSM) Announces That IPLEX Phase II Trial Did Not Meet A Statistically Significant Improvement
Tweet Send to a Friend
Insmed Inc. (Nasdaq: INSM) announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
